Truist raised the firm’s price target on Aflac (AFL) to $105 from $100 and keeps a Hold rating on the shares after its Q3 earnings beat. The total benefit ratio was 49.2%, down from 65.1% in Q3 of 2023, attributable to the remeasurement gains that had an 18-point favorable benefit in the quarter, the analyst tells investors in a research note.